Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label REN001 safety study in primary mitochondrial myopathy
NL-OMON53482Phase 2Not yet recruiting
- Sponsor
- Reneo Pharmaceuticals
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mavodelpar in primary mitochondrial myopathies (PMM), sponsored by Reneo Pharmaceuticals. Primary endpoints: Adverse events, Adverse events leading to discontinuation and 3 more. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
mavodelpar
03
Conditions
primary mitochondrial myopathies (PMM)
Beyond the preview
Go deeper on NL-OMON53482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53482.